<DOC>
	<DOCNO>NCT01777594</DOCNO>
	<brief_summary>Hepatocellular carcinoma ( HCC ) fifth common type cancer worldwide third common cause death cancer . Sorafenib approve therapy treatment advance HCC , need identify drug beneficial patient without unacceptable side effect . Prodrug chemotherapy approach inactive non-toxic agent administer patient get activate within body specific location , result high concentration cytotoxic form tumor location avoid general side effect . G-202 ( mipsagargin ) example prodrug chemotherapy . It activate Prostate Specific Memory Antigen ( PSMA ) , express cancer cell blood vessel solid tumor , normal cell blood vessel normal tissue . It believe activation prodrug G-202 allow drug kill cancer cell . This study evaluate activity safety G-202 patient hepatocellular carcinoma progress take sorafenib . The study evaluate clinical activity safety G-202 administer intravenous infusion three consecutive day 28-day cycle .</brief_summary>
	<brief_title>Study G-202 ( Mipsagargin ) Second-Line Therapy Following Sorafenib Hepatocellular Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<criteria>Informed consent document sign prior performance studyspecific procedure initiation study therapy At least 18 year age ECOG Performance Status 0 1 Histologic cytologic confirmation hepatocellular carcinoma ( HCC ) ChildPugh score A B7 At least one measurable lesion ( preferably liver ) assess within 4 week first administration G202 abdominal CT MRI dynamic phase image liver , pelvic CT MRI contrast , chest CT contrast , bone imaging patient know bone metastasis medically indicate Must receive sorafenib therapy disease progression sorafenib therapy able tolerate sorafenib Sorafenib anticancer therapy must discontinue &gt; 21days prior first administration G202 Adequate hematologic function ( ANC ≥ 1200/mm3 , hemoglobin ≥ 8.5 g/dL , platelet count ≥ 75,000/mm3 ) Adequate hepatic function ( albumin ≥ 2.8 g/dL , AST ALT ≤ 5 x ULN , total bilirubin &lt; 2 mg/dL ) Adequate renal function ( proteinuria level ≤ 2+ , serum creatinine ≤ 1.5 x ULN ) Acceptable coagulation profile ( PT/INR ≤ 2.3 , aPTT ≤ 1.5 x ULN ) Acute toxicity previous therapy ( exclude alopecia ) must resolve ≤ Grade 1 per CTCAE v4.0 Negative serum pregnancy test woman childbearing potential Prior locoregional therapy ( e.g. , transarterial chemoembolization [ TACE ] ) ≤ 4 week prior first administration G202 recover treatmentrelated toxicity . Radiotherapy ≤ 4 week prior first administration G202 recover toxicity ( palliative radiotherapy bone lesion ≤ 2 week prior allow ) Major surgery ≤ 4 week prior first administration G202 Intolerance CT MRI contrast agent Candidate liver transplantation Persistent untreated biliary infection Any GI bleeding within 12 week prior first administration G202 Currently receive fulldose anticoagulation treatment Clinicallysignificant third space fluid accumulation Known CNS metastasis , include brain metastasis leptomeningeal metastasis Known human immunodeficiency virus ( HIV ) positivity Viral hepatitis require antiviral therapy History evidence cardiac risk , include screen QTc interval &gt; 470 msec , clinicallysignificant uncontrolled arrhythmias arrhythmia require treatment ( except atrial fibrillation paroxysmal supraventricular tachycardia ) , history acute coronary syndrome within 6 month ( include myocardial infarction unstable angina , coronary artery bypass graft , angioplasty , stenting ) history congestive heart failure recent ejection fraction &lt; 45 % Uncontrolled hypertension ( systolic BP ≥ 160 diastolic BP ≥ 100 ) Cerebrovascular accident transient ischemic attack within 6 month prior first dose study therapy History pulmonary embolism within 6 month untreated deep venous thrombosis Documentation keratosis follicularis ( also know Darier DarierWhite disease ) Requirement chronic use inhibitor inducer cytochrome ( CYP3A4 ) isoenzymes Known hypersensitivity study drug component , include thapsigargin derivative , polysorbate 20 , propylene glycol Known history another primary malignancy remission least 2 year ( nonmelanoma skin cancer , cervical carcinoma situ squamous intraepithelial lesion allow ) Use investigational agent within 4 week prior first administration G202 Pregnancy nurse Any medical intervention , medical condition , psychiatric condition social circumstance could compromise patient safety and/or adherence study requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>hepatocellular carcinoma</keyword>
	<keyword>HCC</keyword>
	<keyword>liver</keyword>
	<keyword>liver cancer</keyword>
	<keyword>sorafenib</keyword>
</DOC>